Avenacy Introduces Tranexamic Acid Injection in U.S.

Avenacy, a specialty pharmaceutical company headquartered in Schaumburg, Illinois, has announced the launch of Tranexamic Acid Injection, USP in the United States. This new product serves as a therapeutic generic equivalent to Cyklokapron® and has been approved by the U.S. Food and Drug Administration (FDA). Tranexamic Acid Injection, USP is indicated for short-term use in patients with hemophilia, specifically to reduce or prevent hemorrhage and minimize the need for replacement therapy during and after tooth extraction.

The launch of Tranexamic Acid Injection marks a significant milestone for Avenacy, which has rapidly introduced ten essential injectable medications since its inception in October 2023. Jeff Yordon, Co-Founder and CEO of Avenacy, expressed that this achievement underscores the company's commercial expertise in specialty pharmaceuticals. He emphasized that their mission has always been to quickly deliver safe, effective, and high-quality specialty injectables to hospitals and healthcare providers across the United States. The company is also focused on launching several additional products throughout the rest of 2024, which is anticipated to be a transformative year for the business.

Avenacy's Tranexamic Acid Injection, USP is available in 1,000 mg/10 mL (100 mg per mL) 10-pack single-dose vials. The company's commitment to patient safety and streamlined patient care is reflected in the product's packaging and labeling, designed to support accurate medication selection. The product will begin shipping to wholesale partners this week, bolstered by Avenacy's global network of development and contract manufacturing partners who have successfully passed FDA inspections based on cGMP standards.

In the U.S., Tranexamic Acid Injection, USP reported sales of approximately $28 million for the twelve months ending in June 2023. This financial performance highlights the market's demand for this critical medication, which is essential for treating patients with hemophilia in medically supervised settings.

Avenacy is dedicated to supplying crucial injectable medications that cater to various healthcare environments, including acute care hospitals, outpatient clinics, and physician offices. The company employs a rigorous and optimized selection process to build a pipeline of high-quality FDA-approved injectable products, ensuring a resilient portfolio that meets the dynamic needs of today's drug supply chain. With a team of experienced professionals committed to quality and reliability, Avenacy aims to facilitate safe and efficient patient care, establishing itself as a trusted partner in the pharmaceutical industry.

Founded in 2023, Avenacy is based in Schaumburg, Illinois. The company continues to focus on the development and supply of essential injectable medications, maintaining its mission to enhance healthcare delivery through reliable and high-quality pharmaceutical solutions.